News

Article

SCOPE 2023: Reducing Readmissions in High-Risk Patients

Author(s):

Andy Studna, Senior Editor

In an interview at the 2023 SCOPE conference with ACT editor, Andy Studna, Sunny Kumar, MD, partner at GSR Ventures talks about his recently-founded company and its mission to reduce readmissions for high-risk patients with chronic diseases using voice-enabled natural language processing technology.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

      Subscribe Now!
      Related Videos
      2025 DIA Annual Meeting: The Importance of Early Patient Feedback in Digital Endpoint Development
      2025 DIA Annual Meeting: The Importance of Early Patient Feedback in Digital Endpoint Development
      2025 DIA Annual Meeting: Building Patient Centricity into Clinical Trial Software from Day One
      2025 DIA Annual Meeting: Building Patient Centricity into Clinical Trial Software from Day One
      2025 DIA Annual Meeting: Preparing Operational Teams for AI Workflows in Drug Development
      2025 DIA Annual Meeting: Preparing Operational Teams for AI Workflows in Drug Development
      Related Content
      2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
      August 19th 2025

      2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research

      Don Tracy, Associate Editor
      Credit: Crystal light | stock.adobe.com. Stomach cancer, gastric cancer, symptoms, stages, treatment, 3d illustration
      August 19th 2025

      Phase III MATTERHORN Trial Shows Imfinzi Combo Significantly Improves Event-Free Survival in Resectable Gastric and GEJ Cancers

      Davy James
      © iDoPixBox - © iDoPixBox - stock.adobe.com
      August 19th 2025

      Tecentriq and Zepzelca Combo Demonstrates Significant Survival Benefit in Phase III Study for Extensive-Stage Small Cell Lung Cancer

      Andy Studna, Senior Editor
      Credit: Sebastian Kaulitzki | stock.adobe.com
      August 19th 2025

      Phase III BREAKWATER Trial Shows Braftovi-Based Regimen Improves Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer

      Davy James
      © Crystal light - © Crystal light - stock.adobe.com.
      August 19th 2025

      AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab

      Andy Studna, Senior Editor
      SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
      August 19th 2025

      SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity

      Andy Studna, Senior Editor
      © 2025 MJH Life Sciences

      All rights reserved.